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Abstract
Aims: To investigate the association of ABCG1, GALNT2 and HMGCR genes promoter DNA methylation with coronary heart
disease (CHD) and explore the interaction between their methylation status and the CHD patients’ clinical characteristics in
Han Chinese population.
Methods and results:Methylation-specific polymerase chain reaction (MSP) technology was used to examine the role of the
aberrant gene promoter methylation in CHD in Han Chinese population. A total of 85 CHD patients and 54 participants
without CHD confirmed by angiography were recruited. 82.8% of the participants with ABCG1 gene promoter
hypermethylation have CHD, while only 17.4% of the participants without hypermethylation have it. The average age of
the participants with GALNT2 gene promoter hypermethylation is 62.1068.21, while that of the participants without
hypermethylation is 57.2869.87; in the former group, 75.4% of the participants have CHD, compared to only 50% in the
latter group. As for the HMGCR gene, the average age of the participants with promoter hypermethylation is 63.2468.10
and that of the participants without hypermethylation is 57.7969.55; its promoter hypermethylation is likely to be related to
smoking. Our results indicated a significant statistical association of promoter methylation of the ABCG1 gene with
increased risk of CHD (OR= 19.966; 95% CI, 7.319–54.468; P*,0.001; P*: adjusted for age, gender, smoking, lipid level,
hypertension, and diabetes). Similar results were obtained for that of the GALNT2 gene (OR= 2.978; 95% CI, 1.335–6.646;
P* = 0.008), but not of HMGCR gene (OR= 1.388; 95% CI, 0.572–3.371; P* = 0.469).
Conclusions: The present work provides evidence to support the association of promoter DNA methylation status with the
risk profile of CHD. Our data indicates that promoter DNA hypermethylation of the ABCG1 and GALNT2 genes, but not the
HMGCR gene, is associated with an increased risk of CHD. CHD, smoking and aging are likely to be the important factors
influencing DNA hypermethylation.
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Introduction
Coronary heart disease (CHD), a complex disease caused by an
imbalance between blood supply and demand of the myocardium,
is a leading cause of morbidity and mortality worldwide. The
aetiology of CHD is largely attributed to the accumulation of
cholesterol crystals, cell debris, fibrous materials, & minerals in the
intimal layer of the coronary arteries [1–2]. It is well established
that genetic and environmental factors, such as CHD family
history, poor diet, advanced age, smoking habit, hypertension,
diabetes mellitus, and dyslipidemia are associated with an
increased risk of CHD [3]. Among these factors, dyslipidaemia
is known to have a major influence. Several studies have suggested
that an elevated level of total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-C), and a low level of high density
lipoprotein cholesterol (HDL-C) are associated with a worse
prognosis of CHD [4]. Lipid accumulation product (LAP), a
continuous marker of lipid over accumulation, has recently been
proposed to be a good predictor for the risk of cardiovascular
disease [5]. However, the exact role of dyslipidaemia in the
cardiovascular system diseases remains to be determined.
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Recently, increasing evidence indicates that many human
diseases, including cancers and atherosclerosis, are either caused
or influenced by abnormal DNA methylation [6–7]. DNA
methylation is a stable and well understood epigenetic marker. It
refers to the addition of a methyl group to the 5 position of
cytosine in a dinucleotide CpG site. Although controversy still
exists about the effect of the position and size of methylated DNA
segments on regional transcription, it has been well established
that this epigenetic change is associated with transcription
silencing, and loss of methylation (demethylation) promotes, if
not activates, gene expression [8]. One of the major mechanisms
to down-regulate expression of a gene is methylation of a cytosine
and guanine rich area, called CpGislands, in the promoter region
of the gene [9]. A few studies have indicated that DNA promoter
methylation of certain genes is responsible for the susceptibility of
CHD [10–13].
ABCG1, GALNT2 and HMGCR are among the genes
suggested by Genome-wide association study (GWAS) whose
variants are associated with CHD and variations in plasma
lipoproteins [14–16]. These three genes exert their effects on the
pathogenesis and progression of CHD through manipulating the
various lipid pathways. The expression of ABCG1 gene reduces
cholesterol accumulation in macrophages by promoting the
transfer of intracellular cholesterol into HDL-C pathway [15].
GALNT2 gene, which influences O-linked oligosaccharide
biosynthesis, has been shown to be involved in HDL-C regulation
in humans [14,16]. HMGCR gene, on the other hand, is
associated with variation in LDL-C levels [14]. The aims of the
present study are firstly to establish whether abnormal promoter
region methylation of these three genes occurs in the cardiovas-
cular system; secondly to explore the interaction of the methyl-
ation with the participants’ lipid level and a few clinical
characteristics; and thirdly to ascertain whether the aforemen-
tioned methylation contributes to the risk of CHD.
Materials and Methods
Ethics Statement
This study protocol was approved by the Ethical Committee of
Ningbo Lihuili Hospital. The informed written consent was
obtained from all the subjects.
Sample and clinical data
Between 1st of July 2012 and 1st of March 2013,221 patients
were under the care of our Cardiology department in the Ningbo
Lihuili Hospital, Ningbo city of Zhejiang province, China. Each of
them was seen and reviewed by at least two independent
cardiologists. All of their medical records were carefully read.
Among these patients, 85 patients had one or more major
coronary arteries with more than 50% occlusion. They were
included into the case group. Another 54 patients, who do not
have an occlusion at all or a past medical history of any congenital
heart disease, cardiomyopathy, liver or renal diseases, are included
in the non-CHD group. The rest 82 patients were excluded from
our study because of the existence of occlusion of less than 50% in
at least one of their coronary arteries, or their past medical history
of the conditions mentioned above. The details of the inclusion
criteria were presented in our previous publication [17]. All
individuals are Han Chinese living in Ningbo city for at least three
generations. Blood samples were collected in 3.2% citrate sodium-
treated tubes and then stored at 280uC.
Biochemical analyses
Genomic DNA was isolated from peripheral blood samples
using the Wizard Genomic DNA Purification kit (Promega,
Madison, USA). DNA concentrations were determined by the
ultramicro nucleic acid ultraviolet tester (NANODROP 1000,
Wilmington, USA). Plasma levels of TG, TC, HDL, and LDL
were measured using an enzymatic end point assay [18]. The
ApoA, ApoB and ApoE levels were measured by the transmission
turbidimetric method [19]. The plasma Lp(a) concentrations were
determined by a sandwich enzyme-linked immunosorbent assay
method [Macra-Lp(a), SDI, Newark, Delaware]. The concentra-
tions of ALT, AST, ALP and GGT in plasma were measured by
the IFCC reference measurement systems ([20–22]. The ALB level
was worked through the Bromocresol green method [23]. All the
above mentioned procedures were performed following the
standard procedures recommended by the manufacturers.
Epigenetic analysis
Sodium Bisulfite Conversion. The methylation status of a
DNA sequence was measured using sodium bisulfite technology.
Sodium bisulfite preferentially deaminatesun methylated cytosine
residues to thymines (after PCR amplification), whereas methyl-
cytosines remain unmodified. Therefore, bisulfite treatment
introduces a difference to the DNA sequence of methylated and
unmethylated DNA. Sodium bisulfite conversion and DNA
recovery were performed by using EpiTect Bisulfite Kit (Qiagen)
as follows: dilute a total of 2 mg DNA from blood in 40 mL of
RNase-free water in a 200 mL PCR tube; add 85 mL Bisulfite Mix
and 15 mL DNA Protect Buffer into the tube; and perform the
bisulfite DNA conversion using a thermal cycler. DNA was
denaturated at 95uC for 5 minutes, incubated at 60uC for
25 minutes, 95uC for 5 minutes, 60uC for 85 minutes, 95uC for
5 minutes, and 60uC for 175 minutes, and finally held at 20uC
indefinitely. After bisulfite treatment, DNA was ethanol-precipi-
Table 1. Primers for MSP of the ABCG1, GALNT2 and HMGCR genes.
Group Forward primer(59to39) Reversr primer(59to39)
Product
size (bp) Tm
ABCG1 M 59 ATTTGTATTGTGATATCGACGAGAC 39 59 CTTACCTCCTCGATTCTAAACGTAC 39 251 54
ABCG1 U 59 AGATTTGTATTGTGATATTGATGAGAT 39 59 AACTTACCTCCTCAATTCTAAACATAC 39 251 48
GALNT2 M 59 TTATAAGATAGATCGTTTTTTTGTATC 39 59 CCGCTAATATCGATTTTATTTAT 39 263 48
GALNT2 U 59 ATGTTATAAGATAGATTGTTTTTTTGTATT 39 59 AACCCACTAATATCAATTTTATTTAT 39 263 46
HMGCR M 59 TATAAGAGAGAGAGACGTAGGTGATC 39 59 CCCGTACTCGTCCTAACTATAATAA 39 290 55
HMGCR U 59 GTATATAAGAGAGAGAGATGTAGGTGATT 39 59 TAACCCATACTCATCCTAACTATAATAA 39 290 54
MSP: methylation-specific polymerase chain reaction; M: methylation-specific primers; U: unmethylation-specific primers.
doi:10.1371/journal.pone.0102265.t001
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tated and resuspended in 39 m Lelution buffer (Buffer EB) and
stored at 220uC.
Methylation – Specific PCR (MSP). Methylation in the
target CpG regions of ABCG1, GALNT2 and HMGCR genes
promoter in the bisulfite-modified DNA was investigated by
methylation-specific PCR (MSP). Each PCR reaction mix has a
total volume of 50 mL which contains 2 mL bisulfite-modified
DNA, 10 mL 16 KAPA2G buffer (KAPA BIO, United States),
1 mL 0.2 mmol/L deoxynucleotide triphosphate mix (dNTP) mix
(KAPA BIO, United States), 1 mL 0.5 mmol/L of each primer, and
0.5 U of KAPA2G Robust Hotstart DNA Polymerase (KAPA
BIO, United States). The thermo-cyclere condition is as follows:
(1) 95uC for 5 minutes; (2) 10 cycles of 95uC for 30 seconds, Tm-
0.8uC for 30 seconds, and 72uC for 60 seconds; (3) 38 cycles of
95uC for 30 seconds, TmuC for 30 seconds, and 72uC for
60 seconds; (4) 72uC for 10 minutes. PCR products were then
electrophoresed on a 2.5% agarosegel and visualized under UV
illumination. PCR primers were designed by Primer Express
Software v2.0 (ABI). The gene names, locations, primer and probe
sequences are summarized in Table 1.
Statistical analysis
Statistical analyses were performed using the PASW Statis-
tics13.0 software (SPSS, Inc., Somers, NY, USA) and Graph Pad
Table 2. Characteristics of all subjects according to subgroup analysis by CHD status and gender.
Characteristics Subgroup analysis by CHD status Subgroup analysis by gender
CHD(n=85) Non-CHD(n=54) P value Male(n =89) Female(n =50) P value
(Mean ± s.e.) (Mean ± s.e.) (Mean ± s.e.) (Mean ± s.e.)
Age(yrs) 61.3369.22 56.3569.00 0.002 59.2269.52 59.7369.34 0.763
Gender (M/F) (58/67.4) (31/57.4) 0.230 NA NA
Smoking,n(%) 43(50.0) 21(38.9) 0.199 59(66.3) 5(9.8) ,0.001
Hypertension,n(%) 53(61.6) 26(48.1) 0.117 55(61.8) 24(47.1) 0.091
Diabetes,n(%) 25(29.1) 3(5.6) 0.001 15(16.9) 13(25.5) 0.219
TC(mmol/l) 4.561.1 4.3561.0 0.399 4.4861.09 4.3861.02 0.591
TG(mmol/l) 1.9762.82 1.4760.72 0.203 1.9262.76 1.5360.90 0.323
HDL-C(mmol/l) 1.0960.26 1.1060.36 0.784 1.0860.32 1.1260.28 0.397
LDL-C(mmol/l) 2.7260.92 2.6360.76 0.547 2.7460.88 2.6060.83 0.388
ApoAI(g/L) 1.0760.19 1.0460.23 0.320 1.07760.22 1.0360.18 0.142
ApoB(g/L) 0.8560.27 0.8460.21 0.830 0.8560.24 0.8260.26 0.475
ApoE(g/L) 4.1861.34 3.9661.42 0.369 3.9061.18 4.4361.60 0.026
Lp(a)(g/L) 0.4060.34 0.2560.26 0.005 0.3260.35 0.3960.26 0.190
hs-CRP (mg/L) 8.09614.81 3.9063.87 0.014 7.63614.55 4.4764.62 0.134
ALB (g/L) 41.2764.25 40.6666.27 0.498 41.0265.95 41.0663.20 0.958
GLB (g/L) 24.4063.60 26.2664.94 0.011 24.9864.37 25.3764.05 0.597
A/G 1.7260.32 1.6460.29 0.121 1.7160.33 1.6560.28 0.239
ALT (IU/L) 27.06618.19 24.94617.20 0.496 29.01619.65 21.41612.72 0.014
AST (IU/L) 32.95647.19 27.96621.09 0.466 35.07647.33 23.98615.85 0.108
ALP (IU/L) 72.74620.33 70.22624.69 0.512 70.75621.22 73.54623.57 0.472
GGT (IU/L) 40.19640.01 33.81627.74 0.307 44.88639.16 25.25624.82 ,0.001
Values are given as mean6s.e.; NA: denotes not applicable.
CHD: coronary heart disease; TC: total cholesterol; HDL: high density lipoprotein; LDL: low density lipoprotein; ALT: alanine aminotransferase; AST: aspartate
aminotransferase.
doi:10.1371/journal.pone.0102265.t002
Figure 1. Typical methylation analysis result of the ABCG1, GALNT2 and HMGCR genes promoter regions of by MSP. MW: molecular
weight DNA marker (100-bp DNA ladder). 1–6 were CHD patients, 7–12 were Non-CHD controls; M for methylated specific primers; U for the
unmethylated specific primers; PCR product indicated the presence of methylated or unmethylated promoter of ABCG1, GALNT2 and HMGCR for
primer M or primer U.
doi:10.1371/journal.pone.0102265.g001
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(Prism 5). Data are presented as means 6 standard deviation. The
differences of the ABCG1, GALNT2 and HMGCR genes
promoter methylation status between the CHD patients and the
control group were analyzed using a Pearson Chi-square exact
test. The mean group differences for laboratory parameters were
compared by using a Student t-test. Pearson correlation was used
to determine the association between the three genes promoter
methylation status and CHD by assessing odds ratio (ORs) and
95% confidence intervals (95% CI). Cox regression was used to
assess the effect of baseline and traditional risk factors, such as age,
gender, smoking, lipid level, hypertension, and diabetes. All
statistical analyses were two-sided and P value,0.05 was
considered to be statistically significant.
Results
The main clinical and biochemical characteristics of the study
population are shown in table 2. There are 85 CHD patients with
a mean age of 61.3369.22 and 54 healthy subjects with a mean
age of 56.3569.00 participating in the present study. The CHD
patients are older than the non-CHD subjects. There are more
males present in the CHD group than in the non-CHD group.
When all the participants are analysed according to their genders,
the males’ mean age is 59.2269.52 years old, similar to that of the
females, 59.7369.34 years old. The percentage of smokers is
higher in the male group compared to in the female group (66.3%
vs. 9.8%, P,0.001).
Fig. 1 shows a typical example of the MSP products analysed on
an agarose gel for the ABCG1, GALNT2 and HMGCR genes. We
analysed the relationship between the promoter methylation status
of the three genes and various clinical characteristics, such as age,
sex, smoking, lipid level, hypertension, and diabetes mellitus in
Table 3. Firstly, we found that 26.9% of the participants with
ABCG1 gene promoter hypermethylation have diabetes, while
only 6.5% of the participants without hypermethylation have it.
This difference is statistically significant. However, when the Cox
regression was used to adjust the influence of factors such as age,
gender, smoking, lipid level, CHD, and hypertension, the
difference becomes statistically insignificant (P* = 0.0212). 82.8%
of the participants in the former group suffer from CHD. This is
statistically significantly higher than that of the participants in the
latter group which is 17.4% (P,0.001; P*,0.001). The average
age of the participants with GALNT2 gene promoter hypermethy-
lation is 62.1068.21, statistically significantly higher than that of
the participants without hypermethylation which is 57.2869.87
(P= 0.004; P* = 0.008); in the former group, 75.4% of the
participants have CHD, significantly higher than 50% in the
latter group (P= 0.003; P* = 0.008). As for the HMGCR gene, the
average age of the participants with promoter hypermethylation is
63.2468.10, significantly higher than that of the participants
without hypermethylation which is 57.7969.55 (P = 0.003;
P* = 0.014); its promoter hypermethylation is likely to be related
to smoking. In addition, it seems that the DNA promoter
hypermethylation of the three genes is not related to lipid level,
hypertension and gender.
Furthermore, we then analysed the methylation patterns of
ABCG1, GALNT2 and HMGCR genes promoter regions in the
CHD patients and non-CHD subjects. As shown in Fig. 2, the
promoter region of the ABCG1 gene is hypermethylated in 90.5%
of the CHD patients and 29.6% of the non-CHD subjects.
Similarly, the promoter regions of the GALNT2 gene and
HMGCR gene are hypermethylated in a higher percentage of
the CHD patients than the non-CHD subjects (54.1% vs. 27.8%
and 34.1% vs. 22.2% respectively). The promoter methylation of
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the ABCG1, GALNT2 and HMGCR genes was detected in
91.2%, 52.6%, and 31.6% of the male CHD patients, while that of
the male non-CHD subjects is 34.4%, 28.1%, and 21.9%. In the
female study group, the promoter methylation of the three genes
was detected in 89.3%, 57.1%, and 39.3% of the CHD patients
and 22.7%, 27.2%, and 22.7% of non-CHD subjects respectively.
There was a significant statistical association of the promoter
hypermethylation of the ABCG1 gene with CHD risk
(OR=22.859; 95% CI, 8.989–58.135; p,0.001 and
OR=19.966; 95% CI, 7.319–54.468; P*,0.001; P*: adjusted
for age, gender, smoking, lipid level, hypertension, and diabetes).
Hence, ABCG1 promoter methylation status could be used to
predict the risk of CHD in the total study sample. Similar
relationship was found between the methylation status of the
GALNT2 gene promoter region and the risk of CHD
(OR=3.067; 95% CI, 1.474–6.380; p = 0.002 and OR=2.978;
95% CI, 1.335–6.646; P* = 0.008) (Table 4). In contrast, the
methylation status of the HMGCR gene promoter regions is not
shown to be associated with CHD (OR=1.813; 95% CI, 0.829–
3.965; P =0.134 and OR=1.388; 95% CI, 0.572–3.371;
P* = 0.469). As displayed in Table 4, the ABCG1 and GALNT2
gene promoter regions are positively associated with CHD both in
the male group (ABCG1: OR=19.855, 95% CI, 6.148–64.119,
P,0.001; GALNT2: OR=2.840; 95% CI, 1.121–7.194;
P=0.025 and ABCG1: OR=16.291, 95% CI, 4.917–53.974,
P*,0.001; GALNT2: OR=2.717; 95% CI, 1.010–7.309;
P* = 0.048) and the female group (ABCG1: OR=28.333, 95%
CI, 5.964–134.609, P,0.001; GALNT2: OR=3.556; 95% CI,
1.071–11.808; P=0.035 and ABCG1: OR=52.923, 95% CI,
5.329–525.607, P* = 0.001; GALNT2: OR=6.355; 95% CI,
1.248–32.365; P* = 0.026). The analysis in the two gender groups
demonstrates both male- and female-dependent effects of the
ABCG1 and GALNT2 gene promoter methylation status in
prediction of CHD. However, the statistical evidence is not high
enough to support an association between the HMGCR gene
promoter methylation and the CHD in either of the gender group
(Table 4).
Discussion
Coronary heart disease is one of the most prevalent and
preventable health problems that cause high morbidity and
mortality in both the developed and developing countries
worldwide [24]. High level of the circulating LDL-c and low level
of the HDL-c are strong risk factors for CHD [25].
ABCG1 belongs to the ABCG family of reverse half transport-
ers. Similar to ABCA1, ABCG1 exports excess cellular cholesterol
into the HDL pathway and reduces cholesterol accumulation in
the macrophages [16]. Multiple potential transcripts of human
ABCG1 that use alternate exons or promoters have been identified
and found to play an important role in the transportation of
dietary lipid components [26].
Another strong candidate for the HDL-c regulation in humans
is GALNT2, which regulates O-linked oligosaccharide biosynthe-
sis [27]. GALNT2 mutation has been reported to underlie non-
sialyation of APOC3, which in turn leads to the increased LPL
activity in humans [28]. LDL-c levels are significantly associated
with GWAS SNPs near HMG Co-A reductase (HMGCR), the
rate-limiting enzyme for cholesterol biosynthesis [29]. Typical of
GWAS-identified variants, an LDL-associated genetic variant near
HMGCR has an allele frequency of 39% and influences LDL
cholesterol levels by a modest 2.5 mg/dL. However, use of statins,
which inhibit the function of the rate-limiting enzyme, encoded by
HMGCR, in the cholesterol synthesis, typically decreases LDL
cholesterol levels by 20–40%, or ,14–70 mg/dL [30].
Sharma P et al has provided evidence that there is a potential
relationship between the global DNA hypomethylation and locus-
specific hypermethylation in the process of atherosclerosis, which
has yet to be explored [31]. Promoter CpG island hypermethyla-
tion is closely related to gene inactivation and silencing, resulting
in loss of expression of tumour suppressor genes and X-
chromosome inactivation [32–33]. Aberrant promoter region
methylation of tumour-suppressor genes is associated with the
mechanism for carcinogenesis. Altered gene expression and cell
proliferation in atherosclerotic lesions have some similar charac-
teristics of certain solid tumours and thus might share similar
mechanisms that lead to CHD [34]. Indeed, it is conceivable that
epigenetic modifications, especially alteration in DNA methylation
status, are increasingly being recognized as a key factor in the
pathogenesis of complex disorders, including atherosclerosis [9].
Several studies have separately shown that methylation of CpG
islands of the CHD risk genes has a significant role in the
development of CHD. Simon et al found that epigenetic changes
within the ABCA1 gene promoter contribute to the inter-
individual variability in plasma HDL-C concentrations and are
associated with CHD expression [12]. For example, the modula-
tion of methylation-induced FVIIa concentrations was observed
Figure 2. Methylation percent of the ABCG1, GALNT2 and HMGCR genes promoter in the CHD cases and Non-CHD controls according
to subgroup analysis by total samples and gender.
doi:10.1371/journal.pone.0102265.g002
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only in A1A1, where the higher methylation status resulting in
lower FVIIa being more prevalent within the CHD-free group
compared to the CHD group (p = 0.011) [14]. PLA2G7 methyl-
ation might exert its effects on the risk of CHD by regulating the
levels of TC, TG, and ApoB in females. The gender disparities in
the PLA2G7 methylation may have an effect in the molecular
mechanisms underlying the pathophysiology of CHD [11].
Methylation associated inactivation of the ER, a gene in vascular
tissue, may influence atherogenesis and aging of the vascular
system [9]. These examples demonstrate that DNA aberrant
methylation potentially play a predominant role in the pathogen-
esis of cardiovascular disease.
In the present study, methylation status of the promoter region
of the CHD risk genes ABCG1, GALNT2 and HMGCR were
firstly investigated. Our study found a significantly higher
promoter methylation of ABCG1 and GALNT2 in the CHD
group than in the non-CHD group. The promoter region of the
ABCG1, GALNT2 and HMGCR genes was hypermethylated in
90.5%, 54.1% and 34.1% of CHD patients and 29.6%, 27.8%
and 22.2% of non-CHD subjects. There is statistically significant
evidence to show that the ABCG1 gene promoter hypermethyla-
tion increases the risk of CHD in the total samples (OR=22.859;
95% CI, 8.989–58.135; P,0.001 and OR=19.966; 95% CI,
7.319–54.468; P*,0.001). Similar results were obtained for the
GALNT2 gene (OR=3.067; 95% CI, 1.474–6.380; P=0.002 and
OR=2.978; 95% CI, 1.335–6.646; P* = 0.008). However, we
found no convincing association between the DNA methylation of
HMGCR gene promoter and CHD risk. The promoter methyl-
ation of ABCG1 and GALNT2 genes are significantly positively
associated with CHD risk both in the male and the female groups.
In addition, we found a significant association between the
promoter methylation status of the three genes and several clinical
characteristics. This study found that 82.8% of the participants
with ABCG1 gene promoter hypermethylation have CHD, while
only 17.4% of the participants without hypermethylation have it;
the percentage of the participants have diabetes is 26.9% in the
former group and 6.5% in the latter group. The average age of the
participants with GALNT2 gene promoter hypermethylation is
62.1068.21, while that of the participants without hypermethyla-
tion is 57.2869.87; in the former group, 75.4% of the participants
have CHD, compared to only 50% in the latter group. As for the
HMGCR gene, the average age of the participants with promoter
hypermethylation is 63.2468.10 and that of the participants
without hypermethylation is 57.7969.55; its promoter hyper-
methylation is likely to be related to smoking. In the past decade,
several clinical research studies have been focused on the
molecular mechanisms of aberrant DNA methylation in the
development of CHD, but our current understanding into these
processes is limit.
There are some limitations in our study. Firstly, to the best of
our knowledge, this is the first study to analyse the involvement of
the ABCG1, GALNT2 and HMGCR genes promoter methylation
in CHD. The sample size in our study is comparatively small, as
only 85 CHD patients and 54 participants without CHD were
recruited. Hence, further replication studies with larger sample
size are required to confirm our findings. Secondly, as our study
only recruited Han Chinese people, further replication studies of
the relationship between the promoter methylation of the three
genes and the risk of CHD in other different ethnic populations
are needed. In addition, our study was only designed to determine
whether the DNA methylation status of the three genes’ promoter
regions has a predominant role in the development of CHD. The
underlying mechanisms have not been scrutinised. Aberrant
methylation status of these genes could contribute to CHD risk
via manipulating gene expression, affecting protein levels,
influencing blood lipid levels, or even participating in the
pathogenesis of atherosclerosis. Therefore, the relationship
between DNA methylation status and gene expression regulation
will have to be tested in further studies.
In conclusion, the present work has provided supportive
evidence to the link between DNA methylation status and the
cardiovascular risk profile. Our data indicated that the ABCG1
and GALNT2 gene promoter hypermethylation increases the risk
of CHD. However, no convincing association between that of the
HMGCR gene and CHD risk was found. CHD, smoking and
aging are likely to be the important factors influencing DNA
hypermethylation. The aforementioned results can potentially
help improve the current clinical diagnosis and treatment of CHD.
For a better understanding of the pathophysiological processes of
CHD, future studies are required to investigate the relationship
between DNA methylation and gene expression regulation.
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